Company news

Veru Inc. (NASDAQ:VERU) news

Veru Inc. news releases on 6ix. Latest, Sep 8, 2026: Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity…

Veru Inc. (NASDAQ:VERU) news

Press releases & updates

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru : Annual Report for Fiscal Year Ending 09-30, 2025 (Form 10-K)

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

Veru to Present Two Abstracts at ObesityWeek 2025

Veru Announces Pricing of $25 Million Public Offering

Veru Announces Proposed Public Offering

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru Announces Reverse Stock Split

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

Veru to Participate in the Virtual BTIG Obesity Health Forum

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Date of 2024 Annual Meeting of Shareholders

Veru Reschedules Annual Meeting of Shareholders